AptarGroup (ATR) Jefferies London Healthcare Conference 2025 summary

Business overview and performance

• Pharma segment drives nearly 70% of EBITDA, focusing on proprietary drug delivery devices for chronic diseases, with strong growth and profitability metrics in recent years.

• Beauty and closures segments complement pharma, serving health, wellness, and consumer markets, with operational improvements boosting margins.

• Company manages by technology platforms, leveraging precision injection molding, automated assembly, and AI-assisted quality control, owning all intellectual property.

• Sustainability is a core value, with top industry recognitions and a strong commitment to diversity and responsible practices.

• Capital deployment prioritizes pharma, with significant returns to shareholders via dividends and buybacks, and steady CapEx focused on capacity and technology upgrades.

Pharma segment and innovation

• Proprietary drug delivery systems, especially nasal and inhalation, are the main profit engines, with a robust pipeline in chronic and emerging therapeutic areas.

• Acquisitions have expanded capabilities in injectables and active materials, supporting growth in diabetes, cardiovascular, and neurodegenerative treatments.

• Nasal delivery is increasingly used for systemic treatments, with a growing pipeline in areas like GLP-1, mental health, and vaccines.

• Combination medicines ensure recurring revenue streams, as the company’s devices remain integral through patent expirations and generic transitions.

• High market share in respiratory, dermal, and eye care, with injectables and oral delivery offering further growth opportunities.

Growth drivers and outlook

• Injectables business, currently 17% of pharma, is growing rapidly, fueled by GLP-1 and regulatory compliance investments, and could reach 20% or more.

• No anticipated peak in GLP-1 sales due to expanding indications and chronic disease prevalence; growth trajectory expected to continue.

• Annex 1 compliance investments are driving a strong pipeline and are expected to be a sustained growth driver for injectables.

• CapEx needs are steady, with no major new sites planned; incremental investments will focus on equipment and capacity within existing facilities.

• M&A strategy targets technology adjacencies, geographic expansion, and management quality to deepen the competitive moat.